【正文】
3DCRT/IMRT= 70 Gy。 MSKCC: RP術(shù) 后, 185/712 (26%)。ir243。 NCCN guideline216。 Mapping of nodal disease in locally advanced prostate cancer: Rething the clinical target volume for pelvic nodal irradiation based on vascular rather than bony anatomy.216。第五十 頁 ,共五十三 頁 。1. 閉孔淋巴結(jié)要勾畫至恥骨聯(lián)合 (li225。1. S3以下 (yǐxi224。ng)包全髂總骶前淋巴結(jié)IJROBP, 2024 Cm Cm第四十四 頁 ,共五十三 頁 。 CTVs include the vessels (artery and vein) and a 7mm radial margin 216。nqiāng)淋巴結(jié)預(yù)防照射的前列腺癌靶區(qū)勾畫第四十一 頁 ,共五十三 頁 。第三十八 頁 ,共五十三 頁 。前列腺和精囊 (jīngn225。 Large Bowel: 0% 55Gy。 60 Gy 30%216。 55 Gy ≤ 50%216。 from PTV1 volume to PTV2 volume between 46 and 60 Gy.第三十二 頁 ,共五十三 頁 。 CTV = GTV216。 Contour external bladder wall from its apex to the dome.216。Contouring:216。 Immobilization: employ immobilization system that keeps random and systematic errors to acceptable limits第二十八 頁 ,共五十三 頁 。Risk stratification and treatment remendationLow risk Intermediate risk High riskT1–T2aPSA 10 ng/mL GS 7T2b–T2cPSA 10–20 ng/mLGS 7 T3–T4PSA 20 ng/mL GS 8–103DCRT/IMRT= 70 Gy 3DCRT/IMRT = 76 Gy 3DCRT/IMRT ≧ 76 Gy +neoadjuvant and adjuvant ADT第二十七 頁 ,共五十三 頁 。o)指南結(jié)合 (ji233。 S13 presacral lymph nodes 216。 Internal iliac lymph nodes 216。 LNM%= 2/3(PSA) + (Gs – 6)x10216。Prostate Cancer Nodal Spread216。前列腺癌淋巴 (l237。 When treating the SV for prostate cancer, only the proximal – cm be included within the CTVKestin et al IJRO